Tislelizumab: Structural Innovations and Expanding Clinical Horizons in Next‐Generation PD‐1 Immunotherapy

ABSTRACT Tislelizumab is a next‐generation PD‐1 monoclonal antibody developed to overcome the limitations of earlier immune checkpoint inhibitors. By eliminating Fcγ receptor binding, it avoids macrophage‐mediated T‐cell clearance and enhances the antitumor immune response. Unlike conventional PD‐1...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Thy T. Nguyen, Bohan Zhang, Luke Zhong, Xiuyi Liang, Letao Bo
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	Wiley 2025-09-01
Цуврал:	Chronic Diseases and Translational Medicine
Нөхцлүүд:	monoclonal antibodies, immunotherapy PD‐1 tislelizumab
Онлайн хандалт:	https://doi.org/10.1002/cdt3.70017
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!